Nanda Balasubramanian, Ph.D

Bristol Myers Squibb

Tackle challenges in bioanalysis for cutting-edge therapies

Nanda Balasubramanian discusses the pivotal role of bioanalysis in advancing pharmaceutical science. He shares key innovations in bioanalytical techniques to reduce the burden on patients and improve turnaround times of assays. Balasubramanian also addresses the unique challenges of bioanalysis for therapeutic modalities like mRNA therapeutics, CAR-T, and small molecules. Plus, he discusses the need to adapt processes by incorporating lessons learned in the context of new modality drug development.



LIKE 0
Nanda Balasubramanian, Ph.D
Biotherapeutics Gene Editing Precision Medicine

Nanda Balasubramanian, Ph.D

Biography

With over a decade of... More

Nanda Balasubramanian, Ph.D

Bristol Myers Squibb

With over a decade of experience in molecular assays, immunoassays, and bioanalysis, Balasubramanian has served as a bioanalytical lead supporting a wide range of therapies, including biologics, mRNA therapeutics, ASO, Gene Therapy, and CAR-T. Currently working as a Senior Principal Scientist at Bristol Myers Squibb (BMS), he focuses on bioanalysis for CAR-T, gene therapy, and large molecules. Before joining BMS, he held increasingly responsible bioanalytical lead scientist positions at Alexion, Pfizer, and AstraZeneca. Balasubramanian has actively contributed to industry working groups such as AAPS and IQ consortium and has co-authored reviews on bioanalytical strategies and approaches, particularly for new modalities. He completed his postdoctoral research at Yale University School of Medicine, where he applied various techniques, including DNA repair, high-throughput screening, anti-sense oligos, nanoparticles, and gene therapy.